Arcus Biosciences Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
RCUS$18.95+3.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
Exhibit Index
| ExhibitNumber · Exhibit Description · Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Form · File No · Exhibit · Filing Date | |||||
| 3.1 | Amended and Restated Certificate of Incorporation. | 10-Q | 001-38419 | 3.1 | May 9, 2018 |
| 3.2 | Amended and Restated Bylaws. | 8-K | 001-38419 | 3.1 | May 26, 2020 |
| 4.1 | Reference is made to Exhibits 3.1 and 3.2 | ||||
| 4.2 | Description of Common Stock. | 10-K | 001-38419 | 4.3 | February 25, 2021 |
| 10.1 | Non-Employee Director Compensation Program | 8-K | 001-38419 | 10.1 | June 6, 2024 |
| 10.2A | Form of Indemnification Agreement between the Registrant and each of its directors and executive officers. | S-1 | 333-223086 | 10.1 | February 16, 2018 |
| 10.3A | Arcus Biosciences, Inc. Management Cash Incentive Plan. | S-1 | 333-223086 | 10.13 | February 16, 2018 |
| 10.4A | Arcus Biosciences, Inc. Severance Benefits Plan. | 10-K | 001-38419 | 10.4 | February 21, 2024 |
| 10.5A | Amended and Restated Letter Agreement, dated February 14, 2018, between the Registrant and Terry Rosen, Ph.D. | S-1 | 333-223086 | 10.5 | February 16, 2018 |
| 10.6A | Amended and Restated Letter Agreement, dated February 14, 2018, between the Registrant and Juan Carlos Jaen, Ph.D. | S-1 | 333-223086 | 10.6 | February 16, 2018 |
| 10.7A | Offer letter by and between Arcus Biosciences, Inc. and Jennifer Jarrett dated September 10, 2020. | 10-Q | 001-38419 | 10.2 | November 5, 2020 |
| 10.8A | Offer letter by and between Arcus Biosciences, Inc. and Robert C. Goeltz II dated June 30, 2020. | 10-Q | 001-38419 | 10.1 | November 5, 2020 |
| 10.9A* | Letter Agreement, dated January 13, 2025, between the Registrant and Richard Markus, MD., Ph.D. | ||||
| 10.10A | Arcus Biosciences, Inc. 2015 Stock Plan and forms of agreements thereunder. | S-1/A | 333-223086 | 10.2 | March 5, 2018 |
| 10.11A | Arcus Biosciences, Inc. 2018 Equity Incentive Plan (including form agreements for use before January 1, 2021). | S-1/A | 333-223086 | 10.3 | March 5, 2018 |
| 10.12A | Form of Stock Option Notice and Agreement under 2018 Equity Incentive Plan (for use from January 1, 2021). | 10-K | 001-38419 | 10.36 | February 25, 2021 |
| 10.13A | Form of RSU Notice and Agreement under 2018 Equity Incentive Plan (for use from January 1, 2021). | 10-K | 001-38419 | 10.37 | February 25, 2021 |
| 10.14A | Arcus Biosciences, Inc. 2018 Employee Stock Purchase Plan. | S-1/A | 001-38419 | 10.4 | March 5, 2018 |
| 10.15A | Arcus Biosciences, Inc. Amended and Restated 2020 Inducement Plan. | 10-K | 001-38419 | 10.18 | February 23, 2022 |
| 10.16A | Form of Stock Option Grant Notice (2020 Inducement Plan). | 10-K | 001-38419 | 10.26 | March 5, 2020 |
| 10.17A | Form of Restricted Stock Unit Grant Notice (2020 Inducement Plan). | 10-K | 001-38419 | 10.27 | March 5, 2020 |
| 10.18 | Lease, dated September 30, 2015, between the Registrant and Hayward Point Eden I Limited Partnership, as amended on July 22, 2016 and October 12, 2017. | S-1 | 333-223086 | 10.8 | February 16, 2018 |
| 10.19 | Third Amendment dated June 26, 2020 to the Lease agreement dated September 30, 2015 between Arcus Biosciences, Inc. and Hayward Point Eden I Limited Partnership. | 10-Q | 001-38419 | 10.4 | August 6, 2020 |
| 10.20 | Fourth Amendment dated October 16, 2020 to the Lease agreement dated September 30, 2015 between Arcus Biosciences, Inc. and Hayward Point Eden I Limited Partnership. | 10-Q | 001-38419 | 10.3 | November 5, 2020 |
| 10.21 | Fifth Amendment dated April 1, 2021 to the Lease agreement dated September 30, 2015 between Arcus Biosciences, Inc. and Hayward Point Eden I Limited Partnership. | 10-Q | 001-38419 | 10.2 | May 5, 2021 |
| 10.22B | License Agreement, dated December 8, 2016, between Arcus Biosciences, Inc. and Abmuno Therapeutics LLC. | S-1 | 333-223086 | 10.10 | February 16, 2018 |
| 10.23B | License Agreement, dated August 16, 2017, between Arcus Biosciences, Inc. and WuXi Biologics (Cayman) Inc. | S-1 | 333-223086 | 10.11 | February 16, 2018 |
| 10.24C | Amendment No. 1 dated June 27, 2019 to the License Agreement dated August 16, 2017 between Arcus Biosciences, Inc. and WuXi Biologics (Cayman) Inc. | 10-Q | 001-38419 | 10.2 | August 6, 2019 |
| 10.25C | Amendment No. 2 dated March 2, 2020 to the License Agreement dated August 16, 2017 between Arcus Biosciences, Inc. and WuXi Biologics (Cayman) Inc. | 10-K | 001-38419 | 10.28 | March 5, 2020 |
| 10.26C | Amendment No. 3 dated May 10, 2021 to the License Agreement dated August 16, 2017 between Arcus Biosciences, Inc. and WuXi Biologics (Cayman) Inc. | 10-Q | 001-38419 | 10.2 | August 5, 2021 |
| 10.27C | Amendment No. 4 dated December 30, 2022 to the License Agreement dated August 16, 2017 between Arcus Biosciences, Inc. and WuXi Biologics (Cayman) Inc. | 10-K | 001-38419 | 10.28 | February 28, 2023 |
| 10.28 | Assignment Agreement dated November 10, 2020 by and among Arcus Biosciences, Inc., WuXi Biologics (Cayman) Inc. and WuXi Biologics Ireland Limited to the License Agreement dated August 16, 2017. | 10-K | 001-38419 | 10.35 | February 25, 2021 |
| 10.29B | Option and License Agreement, dated September 19, 2017, between Arcus Biosciences, Inc. and Taiho Pharmaceutical Co., Ltd. | S-1 | 333-223086 | 10.12 | February 16, 2018 |
| 10.30B | Amendment No. 1 to Option and License Agreement, dated September 19, 2017, between Arcus Biosciences, Inc. and Taiho Pharmaceutical Co, Ltd. | 10-Q | 001-38419 | 10.1 | November 8, 2018 |
| 10.31C | Memorandum, dated July 27, 2023, between Arcus Biosciences, Inc. and Taiho Pharmaceutical Co., LTD. | 10-Q | 001-38419 | 10.1 | November 7, 2023 |
| 10.32C | Option, License and Collaboration Agreement dated May 27, 2020 between Arcus Biosciences, Inc. and Gilead Sciences, Inc. | 10-Q | 001-38419 | 10.1 | August 6, 2020 |
| 10.33C | Amendment No. 1 to the Option, License and Collaboration Agreement between Arcus Biosciences, Inc. and Gilead Sciences, Inc., dated November 17, 2021 | 10-K | 001-38419 | 10.34 | February 23, 2022 |
| 10.34C | Amendment No. 2 to the Option, License and Collaboration Agreement between Arcus Biosciences, Inc. and Gilead Sciences, Inc., dated May 15, 2023. | 10-Q | 001-38419 | 10.1 | August 7, 2023 |
| 10.35C | Amendment No. 3 to the Option, License and Collaboration Agreement between Arcus Biosciences, Inc. and Gilead Sciences, Inc., dated January 29, 2024. | 10-Q | 001-38419 | 10.1 | May 8, 2024 |
| 10.36C | Amendment No. 4 to the Option, License and Collaboration Agreement between Arcus Biosciences, Inc. and Gilead Sciences, Inc., dated May 10, 2024. | 10-Q | 001-38419 | 10.1 | August 8, 2024 |
| 10.37C | Letter Agreement with Gilead Sciences, Inc., dated July 1, 2022. | 10-Q | 001-38419 | 10.2 | August 3, 2022 |
| 10.38C | Third Amended and Restated Common Stock Purchase Agreement, dated January 29, 2024 between Arcus Biosciences, Inc. and Gilead Sciences, Inc. | SC 13D/A | 005-90423 | 99.1 | January 31, 2024 |
| 10.39C | Amended and Restated Investor Rights Agreement dated January 29, 2024 between Arcus Biosciences, Inc. and Gilead Sciences, Inc. | SC 13D/A | 005-90423 | 99.2 | January 31, 2024 |
| 10.40 | Equity Distribution Agreement, dated as of February 28, 2023, by and among the Registrant, Goldman Sachs & Co. LLC and SVB Securities LLC. | S-3 | 333-270132 | 1.2 | February 28, 2023 |
| 10.41 | Loan & Security Agreement, between the Registrant, Hercules Capital, Inc. and the lenders listed therein, dated August 27, 2024 | 10-Q | 001-38419 | 10.1 | February 28, 2023 |
| 10.42*A | Separation Agreement, between the Registrant and Dimitry Nuyten, dated January 16, 2025. | ||||
| 19.1* | Insider Trading Policy. | ||||
| 23.1* | Consent of independent registered public accounting firm. | ||||
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 31.2* · Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||||
|---|---|---|---|---|---|
| 32.1† · Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||||
| 32.2† · Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||||
| 97.1 | Compensation Clawback Policy. | 10-K | 001-38419 | 97.1 | February 21, 2024 |
| 101.INS | XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | ||||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in exhibit 101) | ||||
*Filed herewith.
AIndicates management contract or compensatory plan or arrangement.
BThe Company has been granted confidential treatment for certain portions of this exhibit. The omitted portions have been filed separately with the SEC.
CThis exhibit omits certain information the Company deems immaterial and either of the type that it treats as confidential or would be competitively harmful if disclosed.
†This certification is deemed not filed for purposes of section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.